Alasdair completed his Bachelor’s degree and PhD at the University of Otago (NZ) looking at the interplay between cellular DNA repair machinery and cancer, using Adenoviruses as a model system. In 2008 Alasdair moved to Cambridge (UK) as a Postdoc where he looked at the fundamentals underpinning breast cancer heterogeneity. Here he reverse-engineered breast cancer from first principles from primary normal human breast cells, exploring the link between genotype and phenotype.
In 2015 Alasdair started Cancer Research UK’s first dedicated genome editing facility at the CRUK Cambridge Institute, specialising in the innovation and application of CRISPR tools in a translational context. Alasdair’s team focus on using CRISPR in a patient-relevant context, authentically modelling disease and performing functional biology in vitro, in vivo and ex vivo. Further, the team focuses on the innovation of CRISPR technologies as tools for discovery and non-obvious applications. Alasdair is an inaugural Editor of The CRISPR Journal (Mary Ann Liebert), and a College Research Associate of Wolfson College Cambridge.